



Jadenu® (deferasirox) – First-time generic

- On November 21, 2019, Alembic launched [AB-rated](#) generic versions of [Jadenu \(deferasirox\)](#) 90 mg and 360 mg tablets.
 - On November 20, 2019, [MSN Laboratories](#) and [Zydus](#) received FDA approval of AB-rated generic versions of Jadenu 90 mg and 360 mg tablets.
 - Launch plans are pending for these generics.
- Jadenu is approved for the treatment of chronic iron overload due to blood transfusions (transfusional iron overload) and for the treatment of chronic iron overload in non-transfusion-dependent thalassemia syndromes.
- Deferasirox is also available as brand Jadenu 180 mg tablets, brand Jadenu 90 mg, 180 mg and 360 mg sprinkle granules, and as generic 125 mg, 250 mg and 500 mg [tablets for oral suspension](#).
 - Generic deferasirox tablets for oral suspension are approved for the treatment of chronic iron overload due to blood transfusions (transfusional iron overload).
- Jadenu carries a boxed warning for renal failure, hepatic failure, and gastrointestinal hemorrhage.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.